Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | ABCB1 | P08183 | 7/20 | 0.54 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.52 |
| ▸ | DRD1 | P21728 | 1/20 | 0.51 |
| ▸ | DRD5 | P21918 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6975839 | 0.85 | ABCB1 (0.55) | TDP1ABCB1HRH3 | |
| SCHEMBL13255332 | 0.82 | DRD2 (0.52) | TDP1ABCB1 | |
| SCHEMBL10278367 | 0.81 | ABCB1 (0.74) | ABCB1 | |
| SCHEMBL6369606 | 0.81 | HRH3 (0.61) | ABCB1HRH3DRD1DRD5 | |
| SCHEMBL3245096 | 0.81 | SLC6A4 (0.51) | TDP1ABCB1 | |
| SCHEMBL3173969 | 0.81 | ABCB1 (0.68) | TDP1ABCB1HRH3DRD1DRD5 | |
| SCHEMBL22099626 | 0.81 | SLC6A2 (0.55) | TDP1ABCB1DRD1DRD5 | |
| SCHEMBL4384644 | 0.81 | TDP1 (0.59) | TDP1ABCB1HRH3DRD1DRD5 | |
| SCHEMBL10675568 | 0.80 | ABCB1 (0.67) | TDP1ABCB1HRH3DRD1DRD5 | |
| SCHEMBL3246821 | 0.78 | DRD1 (0.58) | TDP1ABCB1HRH3DRD1DRD5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100190753-A1 | Methods and Compositions for Treating Amyloid-Related Diseases | BELLUS HEALTH (INTERNATIONAL) LIMITED (CH) | 2010-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100190753-A1 | Methods and Compositions for Treating Amyloid-Related Diseases | APP, PSEN1, PSEN2 | TDP1 686/4885ABCB1 523/4885HRH3 1636/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.